Overview
PT-141 (bremelanotide) is an FDA-approved peptide therapy developed from the melanocortin system, derived originally from Melanotan II. During early Melanotan II clinical trials at the University of Arizona, 9 out of 10 male volunteers experienced spontaneous erections, prompting targeted development of a compound specifically for sexual dysfunction. Unlike PDE-5 inhibitors (Viagra, Cialis), PT-141 acts centrally on the nervous system rather than the vascular system, making it effective for both men and women.
Mechanism of Action
PT-141 activates melanocortin receptors (MC3R and MC4R) in the hypothalamus, directly stimulating neural pathways linked to sexual arousal and desire. This triggers dopamine release and nitric oxide production in key brain areas governing sexual behavior. The central nervous system mechanism is distinct from vascular-acting ED medications, allowing PT-141 to address both desire and arousal components simultaneously. It received FDA approval in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women.
Potential Benefits
- FDA-approved for hypoactive sexual desire disorder (HSDD) in women
- Increases sexual desire and arousal in both men and women
- Acts on central nervous system rather than vascular system
- Effective for individuals who do not respond to PDE-5 inhibitors
- Improves scores on Female Sexual Function Index (FSFI)
- Reduces Female Sexual Distress Scale (FSDS) scores
- Onset of action within 45-90 minutes
Dosage Protocols
The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.
| Typical Range | 0.5-2 mg/dose as needed |
| Beginner | 0.5-1 mg (30-60 min before sexual activity) |
| Intermediate | 1-1.75 mg as needed |
| Advanced | 2 mg as needed (FDA-approved max dose) |
| Cycle Duration | As needed; not intended for continuous daily use |
| Cycle Off | No formal cycling required; use as needed |
FDA-approved as Vyleesi at 1.75 mg subcutaneous. Duration of action 6-12 hours; onset 45-90 minutes. Avoid use more than once per 24 hours. Nausea is dose-dependent — start low and titrate. Taking with anti-nausea medication can help.
Use our Reconstitution Calculator to determine exact syringe units for your protocol.
Routes of Administration
Intranasal Spray Moderate — bypasses first-pass metabolism, direct CNS access for some peptides
Spray into each nostril as prescribed. Prime device before first use. Alternate nostrils between doses.
Read our full Routes of Administration Guide for detailed comparison of all delivery methods.
Stacking Protocols
Popular research stacks involving PT-141:
General Research Protocol
PT-141 is typically run as a standalone compound in research protocols. Stacking with other peptides should be approached cautiously and with clinical guidance.
Explore our complete Peptide Stacking Guide for more combinations and safety considerations.
Reconstitution
| Typical Vial Size | 10mg |
|---|---|
| BAC Water | 1-2ml per 10mg vial |
| Storage | Refrigerate at 2-8°C after reconstitution; Vyleesi auto-injector stored at room temperature |
| Shelf Life | 28 days refrigerated after reconstitution |
Need exact syringe measurements?
Amino Acid Sequence
Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH
Side Effects & Safety
- Nausea (most common, ~40% of patients)
- Flushing and hyperpigmentation
- Transient blood pressure increase
- Headache
- Vomiting
- Injection site reactions
Safety & Contraindications
This information is for educational purposes only. Consult a qualified healthcare provider before using any peptide.
Pregnancy / Lactation
Bleeding Disorders
Active Skin Infection at Injection Site
Pharmacokinetics
| Half-Life | ~2 hours |
|---|---|
| Storage | Store lyophilized peptide at -20°C (long-term) or 2-8°C (short-term, under 30 days). Reconstituted: refrigerate at 2-8°C and use within 28-30 days. Protect from light. Do not freeze reconstituted solution. |
Synergistic Compounds
The following compounds have been studied alongside PT-141 for potential complementary or synergistic effects:
Learn More
References & Further Reading
Latest News & Research
View all articles →
FDA PCAC July 2026: What the BPC-157 peptide compounding review really means
FDA’s Pharmacy Compounding Advisory Committee will review seven unapproved peptides in July 2026. What that process means for BPC-157—and what it doesn’t.
FDA signals enforcement against unapproved compounded GLP-1 drugs: what it means for peptide medicine
The FDA says it will restrict GLP-1 APIs used in mass-marketed unapproved compounded drugs and crack down on advertising that calls them generic versions of branded drugs.
Sublingual compounded peptides: Quicksome claims and what the FDA’s July 2026 PCAC review could change
A press release claims needle-free, sublingual delivery for popular compounded peptides—just as the FDA's PCAC prepares a July 2026 review of seven peptides.
Pemvidutide IMPACT 48-Week MASH Data Lands At EASL 2026 Ahead Of Phase 3
Altimmune's pemvidutide hit 32.4% ELF response, 23.7% triglyceride drop, and 54.5% qFibrosis regression in 212-patient F2/F3 MASH IMPACT Phase 2b at EASL 2026.